JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed

Share this content:
JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed

The introduction of the JAK1 and JAK2 inhibitor ruxolitinib has significantly improved outcomes for some patients with myeloproliferative neoplasms (MPNs); however, the therapeutic armamentarium is still largely inadequate, researchers at the University of Florence, Italy, report in a study published in Blood.

The researchers note treatments have significantly improved for patients with myelofibrosis, extensive splenomegaly, and symptomatic burden with ruxolitinib. However, significant heterogeneity is still seen in patients with essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF).

In their report, the researchers cite an urgent need for treatments to reduce cardiovascular complications, prevent hematological progression, and improve quality of life in patients with MPN.

The researchers suggest that biological profiling techniques may soon be able to help better identify subgroups of patients with more homogeneous clinical behavior who might respond better to more tailored therapies.  They note that biological profiling could assist monitoring patients on therapy and could be incorporated into clinical trials.

A greater understanding of the molecular abnormalities and cellular pathways involved in the pathogenesis of MPN is leading to new approaches. Although new clinical trials with novel target drugs alone or in combination with ruxolitinib are underway, the researchers report that results from some early phase 1 and 2 clinical trials have been disappointing.

Reference

1. Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms.  Blood.  2017;129(6):693-703.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs